{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:37:13Z","timestamp":1788910633863,"version":"build-2803163510"},"reference-count":128,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.blre.2023.101098","type":"journal-article","created":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T05:55:05Z","timestamp":1683611705000},"page":"101098","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["The road to implementation of pharmacokinetic-guided dosing of factor replacement therapy in hemophilia and allied bleeding disorders. Identifying knowledge gaps by mapping barriers and facilitators"],"prefix":"10.1016","volume":"61","author":[{"given":"Tine M.H.J.","family":"Goedhart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron A.A.","family":"Math\u00f4t","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjon H.","family":"Cnossen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.blre.2023.101098_bb0005","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/bloodadvances.2020003264","article-title":"ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease","volume":"5","author":"Connell","year":"2021","journal-title":"Blood Adv"},{"issue":"Suppl. 6","key":"10.1016\/j.blre.2023.101098_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of Hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"21","key":"10.1016\/j.blre.2023.101098_bb0015","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMra1601561","article-title":"Von Willebrand\u2019s disease","volume":"375","author":"Leebeek","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.blre.2023.101098_bb0020","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00228-009-0676-x","article-title":"Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A","volume":"65","author":"Bjorkman","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.blre.2023.101098_bb0025","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1538-7836.2010.03757.x","article-title":"Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring","volume":"8","author":"Bjorkman","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.blre.2023.101098_bb0030","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1365-2141.1995.tb05325.x","article-title":"Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels","volume":"91","author":"Fijnvandraat","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101098_bb0035","series-title":"Richtlijn Diagnostiek en Behandeling van Hemofilie 2020","author":"(NVHB) NVvH","year":"2020"},{"key":"10.1016\/j.blre.2023.101098_bb0040","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221085202","article-title":"International consensus recommendations on the management of people with haemophilia B","volume":"13","author":"Hart","year":"2022","journal-title":"Ther Adv Hematol"},{"issue":"12","key":"10.1016\/j.blre.2023.101098_bb0045","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jth.13867","article-title":"Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH","volume":"15","author":"Iorio","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"7","key":"10.1016\/j.blre.2023.101098_bb0050","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1111\/jth.14153","article-title":"Pharmacokinetics and the transition to extended half-life factor concentrates: communication from the SSC of the ISTH","volume":"16","author":"Ragni","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.blre.2023.101098_bb0055","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/hae.13013","article-title":"The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO","volume":"22","author":"Collins","year":"2016","journal-title":"Haemophilia."},{"issue":"1","key":"10.1016\/j.blre.2023.101098_bb0060","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/hae.13882","article-title":"Clinical application of web accessible population pharmacokinetic service-hemophilia (WAPPS-Hemo): patterns of blood sampling and patient characteristics among clinician users","volume":"26","author":"McEneny-King","year":"2020","journal-title":"Haemophilia."},{"issue":"1","key":"10.1016\/j.blre.2023.101098_bb0065","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/03007995.2021.1991901","article-title":"A survey of physicians\u2019 treatment switching practice in people on long-term prophylaxis for hemophilia in five European countries","volume":"38","author":"van der Sluijs","year":"2022","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"10.1016\/j.blre.2023.101098_bb0070","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1055\/s-0037-1615621","article-title":"Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the international society on thrombosis and Haemostasis","volume":"85","author":"White","year":"2001","journal-title":"Thromb Haemost"},{"issue":"12","key":"10.1016\/j.blre.2023.101098_bb0075","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s40262-020-00904-z","article-title":"Population pharmacokinetic analysis and exploratory exposure-bleeding rate relationship of Emicizumab in adult and pediatric persons with hemophilia A","volume":"59","author":"Retout","year":"2020","journal-title":"Clin Pharmacokinet"},{"issue":"02","key":"10.1016\/j.blre.2023.101098_bb0080","first-page":"208","article-title":"Emicizumab dosing in children and adults with hemophilia A: simulating a user-friendly and cost-efficient regimen","volume":"122","author":"Bukkems","year":"2021","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.blre.2023.101098_bb0085","first-page":"19","article-title":"Scoping studies: towards a methodological framework","volume":"8","author":"O\u2019Malley","year":"2003","journal-title":"Int J Soc Res Methodol"},{"issue":"1","key":"10.1016\/j.blre.2023.101098_bb0090","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"issue":"5","key":"10.1016\/j.blre.2023.101098_bb0095","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/bloodadvances.2020003891","article-title":"Population pharmacokinetics of the von Willebrand factor-factor VIII interaction in patients with von Willebrand disease","volume":"5","author":"Bukkems","year":"2021","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.blre.2023.101098_bb0100","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/j.1538-7836.2007.02588.x","article-title":"von Willebrand factor\/factor VIII concentrate (Haemate\u00ae P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery","volume":"5","author":"Lethagen","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.blre.2023.101098_bb0105","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1365-2516.2011.02583.x","article-title":"Presurgical pharmacokinetic analysis of a von Willebrand factor\/factor VIII (VWF\/FVIII) concentrate in patients with von Willebrand\u2019s disease (VWD) has limited value in dosing for surgery","volume":"17","author":"Di Paola","year":"2011","journal-title":"Haemophilia."},{"issue":"4","key":"10.1016\/j.blre.2023.101098_bb0110","first-page":"533","volume":"11","author":"Mannuccio Mannucci","year":"2013","journal-title":"Blood Transfus"},{"issue":"6","key":"10.1016\/j.blre.2023.101098_bb0115","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1111\/hae.14635","article-title":"Individualised prophylaxis based on personalised target trough FVIII level optimised clinical outcomes in paediatric patients with severe haemophilia A","volume":"28","author":"Huang","year":"2022","journal-title":"Haemophilia"},{"issue":"13","key":"10.1016\/j.blre.2023.101098_bb0120","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1182\/blood.2020005673","article-title":"Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study","volume":"137","author":"Klamroth","year":"2021","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.blre.2023.101098_bb0125","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1365-2516.2011.02539.x","article-title":"Clinical severity of haemophilia A: does the classification of the 1950s still stand?","volume":"17","author":"Den Uijl","year":"2011","journal-title":"Haemophilia."},{"issue":"5","key":"10.1016\/j.blre.2023.101098_bb0130","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1055\/s-0040-1709519","article-title":"Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia A initiated on tertiary prophylaxis","volume":"120","author":"Chowdary","year":"2020","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.blre.2023.101098_bb0135","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2516.2010.02370.x","article-title":"International prophylaxis study group pharmacokinetics expert working G. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia","volume":"17","author":"Collins","year":"2011","journal-title":"Haemophilia."},{"issue":"3","key":"10.1016\/j.blre.2023.101098_bb0140","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1111\/hae.13215","article-title":"Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement","volume":"23","author":"Iorio","year":"2017","journal-title":"Haemophilia."},{"issue":"5","key":"10.1016\/j.blre.2023.101098_bb0145","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1111\/hae.13540","article-title":"Improvement in clinical outcomes and replacement factor VIII use in patients with haemophilia A after factor VIII pharmacokinetic-guided prophylaxis based on Bayesian models with myPKFiT(\u00ae)","volume":"24","author":"Mingot-Castellano","year":"2018","journal-title":"Haemophilia."},{"issue":"2","key":"10.1016\/j.blre.2023.101098_bb0150","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12686","article-title":"Enhanced pharmacokinetics and reduced bleeds in boys with hemophilia A after switching to Kovaltry from other standard half-life factor VIII concentrates","volume":"6","author":"Huang","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"3","key":"10.1016\/j.blre.2023.101098_bb0155","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/hae.13953","article-title":"Recombinant factor VIII fc fusion protein for the treatment of severe haemophilia A: final results from the ASPIRE extension study","volume":"26","author":"Nolan","year":"2020","journal-title":"Haemophilia."},{"issue":"3","key":"10.1016\/j.blre.2023.101098_bb0160","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1538-7836.2008.03270.x","article-title":"Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A","volume":"7","author":"Collins","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2023.101098_bb0165","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.thromres.2018.11.017","article-title":"Clinical outcomes in hemophilia A patients undergoing tailoring of prophylaxis based on population-based pharmacokinetic dosing","volume":"173","author":"Nagao","year":"2019","journal-title":"Thromb Res"},{"issue":"3","key":"10.1016\/j.blre.2023.101098_bb0170","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/hae.12110","article-title":"Monitoring rFVIII prophylaxis dosing using global haemostasis assays","volume":"19","author":"Al Hawaj","year":"2013","journal-title":"Haemophilia."},{"issue":"2","key":"10.1016\/j.blre.2023.101098_bb0175","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/hae.13935","article-title":"A new paradigm for personalized prophylaxis for patients with severe haemophilia A","volume":"26","author":"Delavenne","year":"2020","journal-title":"Haemophilia."},{"key":"10.1016\/j.blre.2023.101098_bb0180","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.thromres.2020.05.005","article-title":"Pharmacokinetics for haemophilia treaters: meaning of PK parameters, interpretation pitfalls, and use in the clinic","volume":"192","author":"Delavenne","year":"2020","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.blre.2023.101098_bb0185","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/hae.13493","article-title":"Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq\u00ae (human-cl rhFVIII) in previously treated patients with severe haemophilia A","volume":"24","author":"Dargaud","year":"2018","journal-title":"Haemophilia."},{"issue":"6","key":"10.1016\/j.blre.2023.101098_bb0190","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1111\/bcp.15185","article-title":"Combining factor VIII levels and thrombin\/plasmin generation: a population pharmacokinetic-pharmacodynamic model for patients with haemophilia A","volume":"88","author":"Bukkems","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.blre.2023.101098_bb0195","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1111\/jth.15106","article-title":"Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: combining thrombin and plasmin generation","volume":"18","author":"Valke","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.blre.2023.101098_bb0200","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.3324\/haematol.2019.217133","article-title":"Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients","volume":"105","author":"Abrantes","year":"2020","journal-title":"Haematologica."},{"issue":"12","key":"10.1016\/j.blre.2023.101098_bb0205","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/psp4.12464","article-title":"Bayesian forecasting utilizing bleeding information to support dose individualization of factor VIII","volume":"8","author":"Abrantes","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"10.1016\/j.blre.2023.101098_bb0210","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1111\/hae.14098","article-title":"Optimal trough levels in haemophilia B: raising expectations","volume":"26","author":"Walsh","year":"2020","journal-title":"Haemophilia."},{"key":"10.1016\/j.blre.2023.101098_bb0215","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2147\/JBM.S84597","article-title":"Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia B","volume":"7","author":"Khayat","year":"2016","journal-title":"J Blood Med"},{"issue":"6","key":"10.1016\/j.blre.2023.101098_bb0220","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1160\/TH16-12-0942","article-title":"Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates","volume":"117","author":"Iorio","year":"2017","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.blre.2023.101098_bb0225","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/FTD.0000000000000625","article-title":"Strategies for individualized dosing of clotting factor concentrates and desmopressin in hemophilia A and B","volume":"41","author":"Preijers","year":"2019","journal-title":"Ther Drug Monit"},{"issue":"7","key":"10.1016\/j.blre.2023.101098_bb0230","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1016\/S2352-3026(21)00163-0","article-title":"Optical or optimal conclusion: pharmacokinetic-guided dosing in haemophilia","volume":"8","author":"Ragni","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2023.101098_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-020-00936-5","article-title":"Population pharmacokinetics of clotting factor concentrates and desmopressin in hemophilia","volume":"60","author":"Preijers","year":"2020","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"10.1016\/j.blre.2023.101098_bb0240","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1055\/s-0035-1552563","article-title":"Individualizing factor replacement therapy in severe hemophilia","volume":"41","author":"Carcao","year":"2015","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2023.101098_bb0245","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720966888","article-title":"Pharmacokinetics in routine haemophilia clinical practice: rationale and modalities-a practical review","volume":"11","author":"Hermans","year":"2020","journal-title":"Ther Adv Hematol"},{"issue":"6","key":"10.1016\/j.blre.2023.101098_bb0250","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1365-2516.2004.01036.x","article-title":"A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia","volume":"10","author":"Ahnstrom","year":"2004","journal-title":"Haemophilia."},{"issue":"5","key":"10.1016\/j.blre.2023.101098_bb0255","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjh.16704","article-title":"Guidelines on the use of prophylactic factor replacement for children and adults with Haemophilia A and B","volume":"190","author":"Rayment","year":"2020","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.blre.2023.101098_bb0260","doi-asserted-by":"crossref","first-page":"e492","DOI":"10.1016\/S2352-3026(21)00135-6","article-title":"Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial","volume":"8","author":"van Moort","year":"2021","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.blre.2023.101098_bb0265","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1055\/s-0039-1677700","article-title":"Impact of adopting population pharmacokinetics for tailoring prophylaxis in Haemophilia A patients: a historically controlled observational study","volume":"119","author":"Stemberger","year":"2019","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.blre.2023.101098_bb0270","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/hae.13977","article-title":"Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS-Hemo project","volume":"26","author":"Hajducek","year":"2020","journal-title":"Haemophilia."},{"issue":"5","key":"10.1016\/j.blre.2023.101098_bb0275","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/hae.13251","article-title":"PK-guided personalized prophylaxis with Nuwiq(\u00ae) (human-cl rhFVIII) in adults with severe haemophilia A","volume":"23","author":"Lissitchkov","year":"2017","journal-title":"Haemophilia."},{"issue":"3","key":"10.1016\/j.blre.2023.101098_bb0280","doi-asserted-by":"crossref","DOI":"10.3390\/jcm6030035","article-title":"The history of clotting factor concentrates pharmacokinetics","volume":"6","author":"Morfini","year":"2017","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.blre.2023.101098_bb0285","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/rth2.12106","article-title":"Performing and interpreting individual pharmacokinetic profiles in patients with hemophilia A or B: rationale and general considerations","volume":"2","author":"Iorio","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"issue":"20","key":"10.1016\/j.blre.2023.101098_bb0290","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1182\/bloodadvances.2021005096","article-title":"Population pharmacokinetic modeling of factor concentrates in hemophilia: an overview and evaluation of best practice","volume":"5","author":"Goedhart","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.blre.2023.101098_bb0295","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40262-019-00809-6","article-title":"Development and validation of a population-pharmacokinetic model for Rurioctacog alfa Pegol (Adynovate((R))): a report on behalf of the WAPPS-Hemo Investigators Ad Hoc subgroup","volume":"59","author":"Chelle","year":"2020","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.blre.2023.101098_bb0300","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1055\/s-0040-1709522","article-title":"A novel, enriched population pharmacokinetic model for recombinant factor VIII-fc fusion protein concentrate in hemophilia A patients","volume":"120","author":"Bukkems","year":"2020","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.blre.2023.101098_bb0305","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/hae.14575","article-title":"Does difference between label and actual potency of factor VIII concentrate affect pharmacokinetic-guided dosing of replacement therapy in haemophilia A?","volume":"28","author":"Goedhart","year":"2022","journal-title":"Haemophilia"},{"issue":"11","key":"10.1016\/j.blre.2023.101098_bb0310","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1111\/bcp.14864","article-title":"Validation of a perioperative population factor VIII pharmacokinetic model with a large cohort of pediatric hemophilia A patients","volume":"87","author":"Preijers","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.blre.2023.101098_bb0315","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/hae.14393","article-title":"Pharmacokinetics of perioperative FVIII in adult patients with haemophilia A: an external validation and development of an alternative population pharmacokinetic model","volume":"27","author":"Zhu","year":"2021","journal-title":"Haemophilia"},{"issue":"4","key":"10.1016\/j.blre.2023.101098_bb0320","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.blre.2018.01.001","article-title":"Setting the stage for individualized therapy in hemophilia: what role can pharmacokinetics play?","volume":"32","author":"Hazendonk","year":"2018","journal-title":"Blood Rev"},{"issue":"SUPPL.1","key":"10.1016\/j.blre.2023.101098_bb0325","first-page":"S23","article-title":"Hemophilia and prophylaxis","volume":"60","author":"Ljung","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"10.1016\/j.blre.2023.101098_bb0330","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1111\/ijlh.12953","article-title":"Measurement of extended half-life recombinant factor IX products in clinical practice","volume":"41","author":"Bowyer","year":"2019","journal-title":"Int J Lab Hematol"},{"issue":"4","key":"10.1016\/j.blre.2023.101098_bb0335","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/hae.14560","article-title":"Revised terminal half-life of nonacog alfa as derived from extended sampling data: a real-world study involving 64 haemophilia B patients on nonacog alfa regular prophylaxis","volume":"28","author":"Tardy","year":"2022","journal-title":"Haemophilia."},{"issue":"2","key":"10.1016\/j.blre.2023.101098_bb0340","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10928-019-09621-y","article-title":"Reproducible pharmacokinetics","volume":"46","author":"Ioannidis","year":"2019","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.blre.2023.101098_bb0345","article-title":"Clarity in reporting parameter variance needed to improve use of published models for simulation applications","volume":"105","author":"Clary","year":"2019","journal-title":"Clin Pharmacol Therap"},{"key":"10.1016\/j.blre.2023.101098_bb0350","doi-asserted-by":"crossref","DOI":"10.1186\/s12959-016-0096-y","article-title":"Individualized prophylaxis for optimizing hemophilia care: Can we apply this to both developed and developing nations?","volume":"14","author":"Poon","year":"2016","journal-title":"Thromb J"},{"issue":"1","key":"10.1016\/j.blre.2023.101098_bb0355","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1182\/asheducation-2017.1.595","article-title":"Using pharmacokinetics to individualize hemophilia therapy","volume":"2017","author":"Iorio","year":"2017","journal-title":"Hematology."},{"issue":"1","key":"10.1016\/j.blre.2023.101098_bb0360","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/hae.12851","article-title":"Facilitating the implementation of pharmacokinetic-guided dosing of prophylaxis in haemophilia care by discrete choice experiment","volume":"22","author":"Lock","year":"2016","journal-title":"Haemophilia."},{"key":"10.1016\/j.blre.2023.101098_bb0365","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2147\/JBM.S363028","article-title":"The impact of pharmacokinetic-guided prophylaxis on clinical outcomes and healthcare resource utilization in hemophilia A patients: real-world evidence from the CHESS II study","volume":"13","author":"Ferri Grazzi","year":"2022","journal-title":"J Blood Med"},{"issue":"4","key":"10.1016\/j.blre.2023.101098_bb0370","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000521360","article-title":"Efficacy of individualized preventive treatment of patients with severe hemophilia A guided by multiple clinical parameters and pharmacokinetics","volume":"145","author":"Wang","year":"2022","journal-title":"Acta Haematol"},{"issue":"1","key":"10.1016\/j.blre.2023.101098_bb0375","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/ped4.12122","article-title":"PK-tailored tertiary prophylaxis in patients with severe hemophilia A at Beijing Children\u2019s hospital","volume":"3","author":"Li","year":"2019","journal-title":"Pediatr Invest"},{"issue":"4","key":"10.1016\/j.blre.2023.101098_bb0380","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1111\/hae.14336","article-title":"Pharmacokinetic-guided prophylaxis improved clinical outcomes in paediatric patients with severe haemophilia A","volume":"27","author":"Huang","year":"2021","journal-title":"Haemophilia"},{"issue":"4","key":"10.1016\/j.blre.2023.101098_bb0385","doi-asserted-by":"crossref","first-page":"8904","DOI":"10.4081\/hr.2021.8904","article-title":"Impact of pharmacokinetics to reduce bleeding in a cohort of patients with severe hemophilia A in a personalized comprehensive management program","volume":"13","author":"Sarmiento Doncel","year":"2021","journal-title":"Hematol Rep"},{"issue":"3","key":"10.1016\/j.blre.2023.101098_bb0390","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","article-title":"Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A","volume":"123","author":"Mahlangu","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101098_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2017.07.003","article-title":"PK-driven prophylaxis versus standard prophylaxis: when a tailored treatment may be a real and achievable cost-saving approach in children with severe hemophilia A","volume":"157","author":"Pasca","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2023.101098_bb0400","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.thromres.2018.12.027","article-title":"Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A","volume":"174","author":"Meg\u00edas-Vericat","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2023.101098_bb0405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2019.08.022","article-title":"Savings without changing: how to use the MyPKfit\u00ae device to improve treatment strategies in a cohort of patients with haemophilia A","volume":"183","author":"Pasca","year":"2019","journal-title":"Thromb Res"},{"issue":"5","key":"10.1016\/j.blre.2023.101098_bb0410","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/hae.13270","article-title":"Predicting dose sparing benefit and bleeding risk of pharmacokinetic-based personalized prophylactic dosing of factor VIII products","volume":"23","author":"Tegenge","year":"2017","journal-title":"Haemophilia."},{"key":"10.1016\/j.blre.2023.101098_bb0415","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.pmu.2019.05.003","article-title":"Investigation of diffusion, practical use, and utility of a medical device for Japanese hemophilia patients in a single institution","volume":"8","author":"Iriuchijima","year":"2019","journal-title":"Personal Med Universe"},{"issue":"3","key":"10.1016\/j.blre.2023.101098_bb0420","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1538-7836.2011.04611.x","article-title":"A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management","volume":"10","author":"Valentino","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.blre.2023.101098_bb0425","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1046\/j.1365-2516.1997.00091.x","article-title":"Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A","volume":"3","author":"Carlsson","year":"1997","journal-title":"Haemophilia."},{"issue":"SUPPL.4","key":"10.1016\/j.blre.2023.101098_bb0430","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2516.2012.02838.x","article-title":"Personalized prophylaxis","volume":"18","author":"Collins","year":"2012","journal-title":"Haemophilia."},{"key":"10.1016\/j.blre.2023.101098_bb0435","doi-asserted-by":"crossref","DOI":"10.1177\/2634853521991517","article-title":"Efficacy of Nuwiq(\u00ae) (Simoctocog alfa) in patients with hemophilia A who changed and adhered to a pharmacokinetic-guided prophylaxis regimen in the NuPreviq Study","volume":"14","author":"Pasi","year":"2021","journal-title":"Clin Med Insights Blood Disord"},{"key":"10.1016\/j.blre.2023.101098_bb0440","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2147\/JBM.S80814","article-title":"Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate(\u00ae)) in hemophilia A","volume":"7","author":"Chowdary","year":"2016","journal-title":"J Blood Med"},{"issue":"5","key":"10.1016\/j.blre.2023.101098_bb0445","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/MBC.0000000000000261","article-title":"Adult severe haemophilia A patients under long-term prophylaxis with factor VIII in routine clinical practice","volume":"26","author":"Mingot-Castellano","year":"2015","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"2","key":"10.1016\/j.blre.2023.101098_bb0450","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1046\/j.1365-2516.1998.00173.x","article-title":"Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis","volume":"4","author":"Carlsson","year":"1998","journal-title":"Haemophilia."},{"key":"10.1016\/j.blre.2023.101098_bb0455","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.thromres.2021.07.009","article-title":"Clinical benefits of a Bayesian model for plasma-derived factor VIII\/VWF after one year of pharmacokinetic-guided prophylaxis in severe\/moderate hemophilia A patients","volume":"205","author":"Meg\u00edas-Vericat","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2023.101098_bb0460","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.thromres.2022.06.001","article-title":"Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products","volume":"216","author":"Meg\u00edas-Vericat","year":"2022","journal-title":"Thromb Res"},{"issue":"10","key":"10.1016\/j.blre.2023.101098_bb0465","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.3324\/haematol.2015.136275","article-title":"A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients","volume":"101","author":"Hazendonk","year":"2016","journal-title":"Haematologica."},{"issue":"11","key":"10.1016\/j.blre.2023.101098_bb0470","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1111\/jth.14292","article-title":"Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery","volume":"16","author":"Preijers","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.blre.2023.101098_bb0475","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-226812","article-title":"Pharmacokinetic-guided dosing of factor VIII concentrate in a morbidly obese severe haemophilia A patient undergoing orthopaedic surgery","volume":"12","author":"Preijers","year":"2019","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.blre.2023.101098_bb0480","article-title":"Pharmacokinetic-guided dosing of factor VIII concentrate in a patient with haemophilia during renal transplantation","volume":"2016","author":"Hazendonk","year":"2016","journal-title":"BMJ Case Rep"},{"issue":"7","key":"10.1016\/j.blre.2023.101098_bb0485","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1080\/08880018.2022.2038316","article-title":"Complicated bleeding challenge and intraoperative safety strategies in a case of hemophilia a with rhabdomyosarcoma","volume":"39","author":"Chaweephisal","year":"2022","journal-title":"Pediatr Hematol Oncol"},{"issue":"6","key":"10.1016\/j.blre.2023.101098_bb0490","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1111\/hae.14649","article-title":"Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: comparison of factor product use, bleed rates and pharmacokinetics","volume":"28","author":"Nummi","year":"2022","journal-title":"Haemophilia"},{"issue":"3","key":"10.1016\/j.blre.2023.101098_bb0495","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/rth2.12118","article-title":"Focusing in on use of pharmacokinetic profiles in routine hemophilia care","volume":"2","author":"Croteau","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"issue":"Suppl. 4","key":"10.1016\/j.blre.2023.101098_bb0500","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/hae.14524","article-title":"Emicizumab state-of-the-art update","volume":"28 Suppl 4","author":"Mahlangu","year":"2022","journal-title":"Haemophilia."},{"issue":"8","key":"10.1016\/j.blre.2023.101098_bb0505","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/17474086.2021.1957826","article-title":"Overcoming the challenges of treating hemophilia in resource-limited nations: a focus on medication access and adherence","volume":"14","author":"Ghosh","year":"2021","journal-title":"Expert Rev Hematol"},{"issue":"Suppl. 7","key":"10.1016\/j.blre.2023.101098_bb0510","first-page":"1","article-title":"Pharmacokinetics, phenotype and product choice in haemophilia B: How to strike a balance?","volume":"20","author":"Berntorp","year":"2014","journal-title":"Haemophilia."},{"issue":"2","key":"10.1016\/j.blre.2023.101098_bb0515","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1055\/s-0040-1708050","article-title":"Design and usability of an electronic health record-integrated, point-of-care, clinical decision support tool for modeling and simulation of Antihemophilic factors","volume":"11","author":"Abdel-Rahman","year":"2020","journal-title":"Appl Clin Inform"},{"issue":"6","key":"10.1016\/j.blre.2023.101098_bb0520","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/jth.13682","article-title":"If you know you will also see: population pharmacokinetics is the way to personalize and optimize prophylaxis in hemophilia","volume":"15","author":"Berntorp","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"8","key":"10.1016\/j.blre.2023.101098_bb0525","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1517\/13543784.2013.798302","article-title":"Investigational drugs for coagulation disorders","volume":"22","author":"Mannucci","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"issue":"8","key":"10.1016\/j.blre.2023.101098_bb0530","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1111\/jth.15395","article-title":"Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: data from the WAPPS database","volume":"19","author":"Versloot","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.blre.2023.101098_bb0535","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/hae.13753","article-title":"Model-based evaluation of low-dose factor VIII prophylaxis in haemophilia A","volume":"25","author":"Brekkan","year":"2019","journal-title":"Haemophilia."},{"issue":"4","key":"10.1016\/j.blre.2023.101098_bb0540","doi-asserted-by":"crossref","DOI":"10.2196\/resprot.6559","article-title":"Data analysis protocol for the development and evaluation of population pharmacokinetic models for incorporation into the web-accessible population pharmacokinetic service - hemophilia (WAPPS-Hemo)","volume":"5","author":"McEneny-King","year":"2016","journal-title":"JMIR Res Protoc"},{"issue":"11","key":"10.1016\/j.blre.2023.101098_bb0545","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1080\/17425255.2016.1214711","article-title":"The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A","volume":"12","author":"McEneny-King","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"10.1016\/j.blre.2023.101098_bb0550","doi-asserted-by":"crossref","first-page":"570","DOI":"10.25122\/jml-2022-0103","article-title":"Expert opinion on current and future prophylaxis therapies aimed at improving protection for people with hemophilia A","volume":"15","author":"Batorova","year":"2022","journal-title":"J Med Life"},{"issue":"2","key":"10.1016\/j.blre.2023.101098_bb0555","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/rth2.12305","article-title":"Pharmacokinetic-tailored approach to hemophilia prophylaxis: medical decision making and outcomes","volume":"4","author":"Croteau","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"10.1016\/j.blre.2023.101098_bb0560","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1111\/hae.13141","article-title":"Experience of tailoring prophylaxis using factor VIII pharmacokinetic parameters estimated with myPKFiT(\u00ae) in patients with severe haemophilia A without inhibitors","volume":"23","author":"\u00c1lvarez-Rom\u00e1n","year":"2017","journal-title":"Haemophilia."},{"issue":"12","key":"10.1016\/j.blre.2023.101098_bb0565","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1080\/17474086.2016.1252670","article-title":"Personalized prophylaxis in people with hemophilia A: challenges and achievements","volume":"9","author":"Ar","year":"2016","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"10.1016\/j.blre.2023.101098_bb0570","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/hae.14295","article-title":"A comparison of MyPKFiT and WAPPS-Hemo as dosing tools for optimizing prophylaxis in patients with severe haemophilia A treated with Octocog alfa","volume":"27","author":"Arvanitakis","year":"2021","journal-title":"Haemophilia."},{"issue":"5","key":"10.1016\/j.blre.2023.101098_bb0575","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/hae.13287","article-title":"The haemtrack home therapy reporting system: design, implementation, strengths and weaknesses: a report from UK Haemophilia Centre doctors organisation","volume":"23","author":"Hay","year":"2017","journal-title":"Haemophilia."},{"issue":"4","key":"10.1016\/j.blre.2023.101098_bb0580","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1055\/s-0038-1675575","article-title":"Smart medication TM, an electronic diary for surveillance of Haemophilia home care and optimization of resource distribution","volume":"39","author":"Mondorf","year":"2019","journal-title":"Hamostaseologie."},{"issue":"3","key":"10.1016\/j.blre.2023.101098_bb0585","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1055\/s-0038-1623531","article-title":"Cross-evaluation of pharmacokinetic-guided dosing tools for factor VIII","volume":"118","author":"Preijers","year":"2018","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.blre.2023.101098_bb0590","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/ccr3.2021","article-title":"Clinical practice of personalized prophylaxis in hemophilia: illustrations of experiences and benefits from two continents","volume":"7","author":"Jackson","year":"2019","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.blre.2023.101098_bb0595","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ejh.12760","article-title":"The first Team Haemophilia Education meeting, 2015, Amsterdam, The Netherlands","volume":"97","author":"Berntorp","year":"2016","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.1016\/j.blre.2023.101098_bb0600","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1055\/s-0033-1354419","article-title":"Tailored versus standard dose prophylaxis in children with hemophilia A","volume":"39","author":"Santoro","year":"2013","journal-title":"Semin Thromb Hemost"},{"issue":"2","key":"10.1016\/j.blre.2023.101098_bb0605","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1586\/17474086.2015.1002465","article-title":"Individualizing prophylaxis in hemophilia: a review","volume":"8","author":"Petrini","year":"2015","journal-title":"Expert Rev Hematol"},{"issue":"S2","key":"10.1016\/j.blre.2023.101098_bb0610","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/hae.13397","article-title":"Individualized PK-based prophylaxis in severe haemophilia","volume":"24","author":"Dargaud","year":"2018","journal-title":"Haemophilia."},{"issue":"3","key":"10.1016\/j.blre.2023.101098_bb0615","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1111\/hae.13470","article-title":"Real life experiences of a PK dosing study\u2014challenges and lessons learned","volume":"24","author":"Mangles","year":"2018","journal-title":"Haemophilia."},{"issue":"5","key":"10.1016\/j.blre.2023.101098_bb0620","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/MPH.0000000000002323","article-title":"Treatment individualization using pharmacokinetic studies and joint ultrasound imaging in pediatric patients with hemophilia","volume":"44","author":"Adramerina","year":"2022","journal-title":"J Pediatr Hematol Oncol"},{"issue":"3","key":"10.1016\/j.blre.2023.101098_bb0625","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/hae.14288","article-title":"Limited sampling strategies for accurate determination of extended half-life factor VIII pharmacokinetics in severe haemophilia A patients","volume":"27","author":"McEneny-King","year":"2021","journal-title":"Haemophilia"},{"issue":"3","key":"10.1016\/j.blre.2023.101098_bb0630","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/rth2.12220","article-title":"Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A","volume":"3","author":"Chowdary","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"4","key":"10.1016\/j.blre.2023.101098_bb0635","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/jth.13271","article-title":"Population pharmacokinetics of plasma-derived factor IX: procedures for dose individualization","volume":"14","author":"Brekkan","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2023.101098_bb0640","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.thromres.2019.10.023","article-title":"A comparison of methods for prediction of pharmacokinetics across factor concentrate switching in hemophilia patients","volume":"184","author":"Yu","year":"2019","journal-title":"Thromb Res"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T15:33:50Z","timestamp":1724772830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X23000590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":128,"alternative-id":["S0268960X23000590"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2023.101098","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The road to implementation of pharmacokinetic-guided dosing of factor replacement therapy in hemophilia and allied bleeding disorders. Identifying knowledge gaps by mapping barriers and facilitators","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2023.101098","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101098"}}